Novartis India Limited will hold its analyst and institutional investor meeting on Thursday, September 10, 2026. The company updated the schedule from the previously announced September 11 date, maintaining the 4:00 pm start time.

Meeting Details

The event is scheduled for 4:00 pm and will be held in Mumbai. It operates as a general group meeting available through both virtual and physical modes. The company noted that the schedule may change due to exigencies on the part of investors, analysts, or the company.

Participation and Disclosure

Participants interested in attending are requested to confirm their presence by writing to investor.relations@nilpharma.co.in . The company emphasized that discussions will refer only to publicly available information. No unpublished price-sensitive information will be shared during the session.

The presentation for the meeting will be made available before the event on the BSE Limited website and the company’s official website at https://nilpharma.co.in/ . The intimation was issued pursuant to Regulation 30 read with Schedule III Part A Para A sub-para 15 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Chandni Maru, Company Secretary and Compliance Officer, signed the disclosure.

Novartis announced that its global Phase III HARBOR study evaluating del-desiran for myotonic dystrophy type 1 (DM1) did not meet its primary endpoint. The trial failed to demonstrate statistically significant improvement versus placebo on video hand opening time, a measure of hand myotonia.

Novartis reported evidence of clinical activity in secondary endpoints and exploratory analyses. Safety findings were generally consistent with previously reported data. The company is evaluating the full dataset to determine the appropriate development path.

Pipeline Progress

Despite the setback, Novartis continues to advance its antibody oligonucleotide conjugate (AOC) pipeline. The company secured FDA priority review for delpacibart zotadirsen in Duchenne muscular dystrophy with exon 44 skipping mutations. It also plans an FDA meeting for delpacibart braxlosiran in facioscapulohumeral muscular dystrophy based on positive Phase I/II biomarker data.

Financial Guidance

Novartis maintained its five-year sales compound annual growth rate (CAGR) guidance of 5-6% for 2025-2030. This outlook remains unchanged despite the clinical trial outcome.

What the Numbers Show

The divergence between the missed primary endpoint and positive secondary signals suggests complex disease biology. While vHOT failed to show statistical significance, exploratory analyses indicated some clinical activity. This pattern implies that while the drug may have biological effect, it may not sufficiently address the specific motor function metric used as the primary success criterion in this trial design.